The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) to set a negotiated price for

At no point on Thursday did anyone from the administration mention Medicare drug price negotiations, a key part of the Inflation Reduction Act which allows federal officials to negotiate the price of certain drugs. Trump has ridiculed the program, and no Republicans voted for the IRA when it passed in 2022.

Health Affairs' Jeff Byers welcomes Rachel Sachs from Washington University in St. Louis and Deputy Editor Chris Fleming back to the pod to discuss CMS' final guidance for the latest round of the Medicare drug price negotiation program.

By Patrick Wingrove and Puyaan Singh (Reuters) -AbbVie said on Friday the Trump administration was pushing for steeper cuts in this year's Medicare drug price negotiations, which in 2024 yielded discounts of as much as 79%.

WASHINGTON — The Trump administration is expected to announce the results of the second round of Medicare drug-price negotiations soon.

The Biden administration is working on forcing the pharmaceutical industry to lower the cost of popular drugs for Medicare Part D recipients. A federal judge has ruled against the pharmaceutical industry in its attempt to get the court to say the Biden ...

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new pricing initiative.

As the Trump administration begins to make its mark on the Medicare drug price negotiation program and pursue its own policies on prescription drugs, litigation over program continues. In the two years since the first case challenging the program was filed ...

Topping the list are Novo Nordisk's blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, which are considered one product in the talks since they all share the same active ingredient: semaglutide. Those treatments ...

Novo Nordisk said on Wednesday it had agreed a price under the U.S. Medicare scheme for semaglutide, the active ingredient in its key drugs Ozempic and Wegovy, in a deal that some analysts said sounded less onerous than feared.